Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen s Revenues Rise in Q4; Net Loss Remains Flat

NEW YORK, Feb. 17 (GenomeWeb News) - Ciphergen Biosystems today reported increased revenues, along with stable losses and R&D expenses, for the last quarter of 2003.

 

Revenues for the quarter were $15.2 million, up from $13.6 million during the same period in 2002.

 

R&D expenses totaled $6.1 million, almost the same as during the year-ago period.

 

The company's net loss for the quarter stayed stable at $6.7 million, or $.23 per share, compared to $6.7 million, or $.25 per share, during the same quarter a year ago.

 

As of Dec. 31, Ciphergen had cash and investments of $47.3 million.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.